AstraZeneca Diabetes Drug Combo Faces Launch Delay As FDA Asks For More Clinical Trial Data Drug company AstraZeneca's launch for its new diabetes treatment has been postponed as FDA did not approve the company's application. FDA requires more clinical trial data for the new treatment. by Alyssa Navarro